Search

Your search keyword '"Felipe Samaniego"' showing total 7 results
Start Over Author "Felipe Samaniego" Journal leukemia & lymphoma
7 results on '"Felipe Samaniego"'

1. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

Author

Erin Taylor, Felipe Samaniego, Loretta J. Nastoupil, Lei Feng, Sattva S. Neelapu, Peter McLaughlin, Fredrick B. Hagemeister, Barbara Pro, Nathan Fowler, Maria Alma Rodriguez, and Michelle A. Fanale

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Follicular lymphoma, Ibritumomab tiuxetan, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Yttrium Radioisotopes, B-cell lymphoma, Lymphoma, Follicular, Mitoxantrone, business.industry, Antibodies, Monoclonal, Hematology, Radioimmunotherapy, medicine.disease, Fludarabine, Regimen, Treatment Outcome, 030220 oncology & carcinogenesis, Rituximab, business, 030215 immunology, medicine.drug
Abstract

R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) can induce molecular remissions in indolent lymphoma. The addition of 90yttrium ibritumomab tiuxetan (90YIT) radioimmunotherapy following first-line induction treatment in patients with advanced follicular lymphoma (FL) may improve remission rates. We now report 10-year follow-up results from our sequential treatment approach with an abbreviated regimen of R-FND followed by 90YIT consolidation and rituximab maintenance. Forty-nine patients were enrolled; 47 received treatment. Patients had high-risk (FLIPI score ≥3) FL of grade 1-3A and stage III/IV with adequate hematologic function. Following R-FND, the complete and partial response rates were 91% and 8.5%, respectively. After 90YIT consolidation, the CR rate increased to 97%. The 10-year PFS rate was 49%. The most common non-hematologic, grade 3 or 4 adverse events were fatigue, dyspnea, and myalgia. Five developed myelodysplastic syndrome (MDS). This treatment approach is most appropriate in FLIPI-based high-risk patients whose outlook with standard therapy is inadequate.

Published
2020

2. Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement

Author

Sattva S. Neelapu, Bouthaina S. Dabaja, Michael W. Morrison, Felipe Samaniego, Linda Chi, Paolo Strati, Raphael E Steiner, Luis Fayad, Chelsea C. Pinnix, Philip A. Thompson, Grace Watson, Rashmi Kanagal-Shamanna, Fateeha Furqan, and Loretta J. Nastoupil

Subjects
Central Nervous System, Oncology, Cancer Research, medicine.medical_specialty, Central nervous system, Marginal zone lymphoma, Article, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Piperidines, immune system diseases, hemic and lymphatic diseases, Internal medicine, medicine, Humans, B cell, Extramural, business.industry, Adenine, Lymphoma, B-Cell, Marginal Zone, Hematology, medicine.disease, Lymphoma, Pyrimidines, medicine.anatomical_structure, chemistry, 030220 oncology & carcinogenesis, Ibrutinib, Pyrazoles, business, 030215 immunology
Abstract

Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin Lymphoma (NHL) that can be further classified into 3 sub-types: nodal, extra-nodal and splenic [1]. MZL rarely involves the central ne...

Published
2020

3. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

Author

Sattva S. Neelapu, Collin K. Chin, Loretta J. Nastoupil, Mansoor Noorani, Maria Alma Rodriguez, Christopher R. Flowers, Jason R. Westin, Preetesh Jain, Felipe Samaniego, Frederick B. Hagemeister, Nathan Fowler, Yun Qing, Lei Feng, and Luis Fayad

Subjects
Cancer Research, business.industry, Extramural, Hematology, medicine.disease, Lymphoma, 03 medical and health sciences, 0302 clinical medicine, Oncology, immune system diseases, hemic and lymphatic diseases, 030220 oncology & carcinogenesis, Cancer research, Medicine, In patient, Rituximab, business, Indolent lymphomas, B-cell lymphoma, 030215 immunology, medicine.drug
Abstract

Histologic transformation of indolent lymphomas account for 13% of de novo presentations of diffuse large B-cell lymphoma (DLBCL) [1]. Although historically associated with poor outcomes in compari...

Published
2020

4. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

Author

Sattva S. Neelapu, Paolo Strati, Mohamed Amin Ahmed, Hun J. Lee, Michael Wang, Maria Alma Rodriguez, Loretta J. Nastoupil, Fredrick B. Hagemeister, Ranjit Nair, R. Eric Davis, Nathan Fowler, Lei Feng, Simrit Parmar, Raphael E Steiner, Felipe Samaniego, Christopher R. Flowers, Jason R. Westin, Luis Fayad, Mansoor Noorani, Sairah Ahmed, and Swaminathan P. Iyer

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Hematology, medicine.disease, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Oncology, immune system diseases, hemic and lymphatic diseases, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, Mantle cell lymphoma, business, 030215 immunology
Abstract

In 2 randomized phase 3 trials BR resulted in longer progression-free survival (PFS) than frontline R-CHOP in patients with indolent and mantle cell lymphoma. However, in subset analyses of follicu...

Published
2020

5. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era

Author

Luis Fayad, Fredrick B. Hagemeister, Nathan Fowler, Michelle A. Fanale, Michael L. Wang, Sattva S. Neelapu, Bei Hu, Sanam Loghavi, Yasuhiro Oki, Felipe Samaniego, Jason R. Westin, Hun J. Lee, Loretta J. Nastoupil, and Beenu Thakral

Subjects
Cancer Research, Retrospective review, business.industry, Hematology, medicine.disease, Lymphoma, Extranodal Disease, 03 medical and health sciences, 0302 clinical medicine, Oncology, immune system diseases, hemic and lymphatic diseases, 030220 oncology & carcinogenesis, medicine, Cancer research, Rituximab, CD5, business, neoplasms, Diffuse large B-cell lymphoma, 030215 immunology, medicine.drug
Abstract

CD5+ diffuse large B-cell lymphoma (DLBCL), NOS represents a distinct subset of DLBCL associated with poorer outcomes and extranodal disease. We analyzed characteristics and outcomes for 10...

Published
2019

6. Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy

Author

Joseph D. Khoury, Loretta J. Nastoupil, Satva S. Neelapu, Luis Fayad, Bouthaina S. Dabaja, Felipe Samaniego, T.Y. Andraos, Jillian R. Gunther, Chelsea C. Pinnix, Nathan Fowler, Sweet Ping Ng, Sarah A. Milgrom, and Zeina Ayoub

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Treatment outcome, Follicular lymphoma, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Combined Modality Therapy, Grade 3 Follicular Lymphoma, Stage (cooking), Lymphoma, Follicular, Aged, Neoplasm Staging, Limited Stage, Chemotherapy, business.industry, Hematology, Middle Aged, Prognosis, medicine.disease, Optimal management, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, Female, Neoplasm Grading, business, Biomarkers, 030215 immunology
Abstract

Controversy exists regarding the optimal management of limited stage grade 3 follicular lymphoma (FL3). We assessed the treatment outcomes of 190 consecutive patients with stage I-II FL. Fifty two patients had FL3 disease, in whom the median age was 55 years. At a median follow-up of 65 months, 5-year progression-free survival (PFS) and overall survival (OS) rates were 76.6% and 87.6%, respectively. Patients receiving systemic therapy followed by radiation therapy (RT) had a significantly better PFS (

Published
2019

7. Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different primary malignancy

Author

Jeff Hosry, Minas P. Economides, Parag Mahale, Harrys A. Torres, Francesco Turturro, Felipe Samaniego, and Bruno Palma Granwehr

Subjects
Male, Oncology, Cancer Research, medicine.medical_specialty, Biopsy, Hepatitis C virus, Hepacivirus, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Internal medicine, medicine, Humans, Neoplasm Staging, Clinical Oncology, business.industry, Lymphoma, Non-Hodgkin, Neoplasms, Second Primary, Primary malignancy, Hematology, Second primary cancer, Combined Modality Therapy, Hepatitis C, Case-Control Studies, 030220 oncology & carcinogenesis, Hodgkin lymphoma, Female, 030211 gastroenterology & hepatology, Neoplasm Grading, Tomography, X-Ray Computed, business
Abstract

This study will be presented in part at the 52nd Annual Meeting of American Society of Clinical Oncology (ASCO), 3–7 June 2016, Chicago, IL.Chronic hepatitis C virus (HCV) infection affects more th...

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results